All In Biotech

NDA 021252 · Abbvie

Canasa

Mesalamine · Rectal · Aminosalicylate

Priority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2001

Jan 5, 2001

Approved uses

3

Original approval plus efficacy supplements

Registered trials

188

77 Phase 3, 14 recruiting

FAERS reports

28,963

25,161 serious, 1,991 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 14, 2026.

CANASA is indicated in adults for the treatment of mildly to moderately active ulcerative proctitis. CANASA is an aminosalicylate indicated in adults for the treatment of mildly to moderately active ulcerative proctitis. ( 1 )

Mechanism: The mechanism of action of mesalamine is not fully understood, but appears to be a topical anti-inflammatory effect on colonic epithelial cells. Mucosal production of arachidonic acid metabolites, both through the cyclooxygenase pathways, i.e., prostanoids, and through the lipoxygenase pathways, i.e., leukotrienes and hydroxyeicosatetraenoic acids, is increased in patients with ulcerative colitis, and it is possible that mesalamine diminishes inflammation by blocking cyclooxygenase and inhibiting prostaglandin production in the colon.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • CANASA · MESALAMINE 500MG · SUPPOSITORY, RECTAL · Discontinued
  • CANASA · MESALAMINE 1GM · SUPPOSITORY, RECTAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Mesalamine" as an intervention, any sponsor and status, largest first.

All 188 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use6,585
  • colitis ulcerative4,668
  • drug ineffective4,551
  • condition aggravated3,424
  • diarrhoea2,723
  • haematochezia2,523
  • fatigue2,332
  • abdominal pain2,214
  • weight decreased1,988
  • headache1,960
  • nausea1,929
  • pyrexia1,863

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004109
2005154
2006113
2007159
2008580
2009150
2010292
2011725
2012662
2013232
2014294
2015374
2016466
2017483
2018683
2019827
20201,226
20212,470
20224,197
20234,314
20244,054
20254,005
20262,393

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Canasa (Mesalamine)

2024 spending

$1.2M

Beneficiaries

176

842 claims

Per beneficiary

$6,839

$36.06 per unit

View as table
YearSpending
2020$9,738,251
2021$2,596,751
2022$1,749,734
2023$1,375,683
2024$1,203,660

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 263 on PubMed

Sponsor: AbbVie

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.